Table 1. Primary cells and cell lines... | American Society of Hematology

Table 1.

Primary cells and cell lines analyzed for the presence of the cellular ligand specific to the EMR2/1-5 isoform

Primary cells	EMR2-ligand binding affinity*
PB lymphocytes, B + T†	+/-
Monocytes	+/-
Monocyte-derived Mφs, days 1-5	++
Neutrophils	-
Erythrocytes	-
Dermal fibroblasts	++
Cell lines
HL-60‡	-
THP-1‡	-
MonoMac6‡	-
U937‡	-
K562‡	-
HEL‡	-
Daudi	-
H9	-
Jurkat	-
A20	-
HEK293T	++++
Hep3B	+
HepG2	+/-
HeLa	+++
NIH3T3	++++
RAW	+
COS-7	++++
CHO-K1	++++

Primary cells	EMR2-ligand binding affinity*
PB lymphocytes, B + T†	+/-
Monocytes	+/-
Monocyte-derived Mφs, days 1-5	++
Neutrophils	-
Erythrocytes	-
Dermal fibroblasts	++
Cell lines
HL-60‡	-
THP-1‡	-
MonoMac6‡	-
U937‡	-
K562‡	-
HEL‡	-
Daudi	-
H9	-
Jurkat	-
A20	-
HEK293T	++++
Hep3B	+
HepG2	+/-
HeLa	+++
NIH3T3	++++
RAW	+
COS-7	++++
CHO-K1	++++

The plus (+) and minus (-) signs indicate relative fluorescence intensity.

Determined by the fluorescence intensity of the FACS-based assay.

Cells were treated with or without PHA-L (2 μg/mL for 2, 6, and 24 hours).

Cells were treated with or without PMA (10 ng/mL for 2 days).